QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biocryst-announced-data-showing-reductions-in-attack-rates-in-hae-patients-with-normal-c1-inhibitor-after-beginning-orladeyo-treatment

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angi...

 biocryst-pharmaceuticals-form-4-filings-shows-cco-charles-k-gayer-bought-30000-shares-at-an-average-price-of-547share-ceo-jon-p-stonehouse-bought-30000-shares-at-an-average-price-of-555share-steven-k-galson-bought-21940-shares-at-an-average-price-of-549share--helen-m-thackray-bought-30000-shares-at-an-average-price-of-586share-anthony-doyle-bought-36300-shares-at-an-average-price-of-557share

- SEC Filing

 jmp-securities-maintains-market-outperform-on-biocryst-pharma-raises-price-target-to-15

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...

 hc-wainwright--co-reiterates-buy-on-biocryst-pharma-maintains-30-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $30 price target.

 needham-reiterates-buy-on-biocryst-pharma-maintains-12-price-target

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $12 price target.

 biocryst-pharmaceuticals-fantastic-q1-earnings-rides-on-outstanding-orladeyo-performance

BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by...

 needham-reiterates-buy-on-biocryst-pharma-maintains-12-price-target

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $12 price target.

 whats-going-on-with-biocryst-stock-after-earnings

BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67...

 li-auto-posts-q4-earnings-joins-teva-pharmaceutical-and-other-big-stocks-moving-higher-in-mondays-pre-market-session

U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday.

 biocryst-pharma-q4-adjusted-eps-028-misses-024-estimate-sales-9340m-beat-9001m-estimate

BioCryst Pharma (NASDAQ:BCRX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0...

 earnings-scheduled-for-february-26-2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on...